Patient-reported outcomes in multiple myeloma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 2, Issue 4, 2004, Pages 379-383

  Lee, Stephanie J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Multiple myeloma; Pain; Patient reported measures; Quality of life

Indexed keywords

ARTICLE; HUMAN; MULTIPLE MYELOMA; PATIENT SATISFACTION; TREATMENT OUTCOME;

HUMANS; MULTIPLE MYELOMA; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 70350511902     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2004.0031     Document Type: Article

References (26)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
3. Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol 2003;120:10-17.
4. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-3454.
5. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
6. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-679.
7. Wittes RE. Antineoplastic agents and FDA regulations: square pegs for round holes? Cancer Treat Rep 1987;71: 795-806.
8. Wisloff F, Eika S, Hippe E, et al. Measurement of healthrelated quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1996;92:604-613.
9. Wisloff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1997;97:29-37.
10. Stead ML, Brown JM, Velikova G, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol 1999;104: 605-611.
11. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
12. Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual, 3rd ed. Brussels, Belgium: European Organsation for Research and Treatment of Cancer; 2001.
13. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales. Evanston, IL: Northwestern University; November 1997.
14. Salmon SE, Cassady JR. Plasma cell neoplasms. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, vol 2, 5th ed. Philadelphia, PA: Lippincott-Raven Publishers; 1997:2344-2387.
15. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23: 129-138.
16. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 1982;50: 893-899.
17. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-493.
18. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-197.
19. Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card: A valid instrument for the evaluation of cancer pain. Cancer 1987;60:1151-1158.
20. Poulos AR, Gertz MA, Pankratz VS, Post-White J. Pain, mood disturbance, and quality of life in patients with multiple myeloma. Oncol Nurs Forum 2001;28:1163-1171.
21. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
22. Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alphainterferon. The Nordic Myeloma Study Group. Br J Haematol 1996;94:324-332.
23. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494.
24. Gulbrandsen N, Wisloff F, Brinch L, et al. Health-related quality of life in multiple myeloma patients receiving highdose chemotherapy with autologous blood stem-cell support. Med Oncol 2001;18:65-77.
25. Zee B, Cole B, Li T, et al. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol 1998;16:2834-2839.
26. Porcher R, Levy V, Fermand JP, et al. Evaluating high dose therapy in multiple myeloma: use of quality-adjusted survival analysis. Qual Life Res 2002;11:91-99.